The Experts below are selected from a list of 276 Experts worldwide ranked by ideXlab platform

Lunan Wang - One of the best experts on this subject based on the ideXlab platform.

  • Strategies for active TNF-α vaccination in rheumatoid arthritis treatment
    Vaccine, 2013
    Co-Authors: Tingting Jia, Yang Pan, Lunan Wang
    Abstract:

    Local overexpression of tumor necrosis factors alpha (TNF-α) is critically involved in the inflammatory response and tissue destruction of rheumatoid arthritis (RA). Currently, the blockade of TNF-α by passive immunotherapy is indeed efficacious in the treatment of RA, but it still present some disadvantages. Induction of high level of anti-TNF-α neutralizing autoantibodies by TNF-α Autovaccine has been developed to avoid these shortcomings. This review is to briefly introduce several vaccination approaches that have been used to induce a B cell response, including coupled TNF-α (entire/peptide) with a carrier protein, modified TNF-α with foreign Th cell epitopes, and engineered DNA vaccine. These methods showed remarkable therapeutic efficiency in experimental animals which indicated that active TNF-α immunization would be a promising and cost-effective new treatment option for RA.

Changli Jiang - One of the best experts on this subject based on the ideXlab platform.

  • The preventive effect of adjuvant-free administration of TNF-PADRE Autovaccine on collagen-II-induced rheumatoid arthritis in mice.
    Cellular immunology, 2009
    Co-Authors: Yi Wan, Shi-fang Yuan, Xiaochang Xue, Xin Qin, Cun Zhang, Weihua Wang, Changli Jiang, Yan Liu
    Abstract:

    Adjuvants are necessary to elicit high titers of antibodies in vaccine-immunization procedures. We previously developed a mouse tumor necrosis factor-α (TNF-α) Autovaccine (mTNF-PADRE) capable of inducing anti-TNF-α antibodies. In this study, we investigated the therapeutic effect of adjuvant-free administration of the Autovaccine on collagen-type-II-induced rheumatoid arthritis (CIA) in mice. Our results showed that the vaccine could ameliorate the symptoms of CIA in mice. In addition, this study suggests that it is possible to control the antibody levels in mice immunized with mTNF-PADRE without adjuvant.

  • Amelioration of experimental autoimmune encephalomyelitis by BLyS Autovaccine
    Vaccine, 2008
    Co-Authors: Xiaochang Xue, Xin Qin, Cun Zhang, Weihua Wang, Changli Jiang, Yanjie You, Guodong Feng, Yan Liu
    Abstract:

    The B-lymphocyte stimulator (BLyS) is implicated in various pathophysiological processes. The overexpression of BLyS has been observed in some human diseases, including systemic lupus erythematosus, rheumatoid arthritis, Sjogren's syndrome, and multiple sclerosis. This feature suggests that BLyS may be a therapeutic target for some human autoimmune diseases. We developed a therapeutic vaccine by coupling a tetanus toxoid T-helper cell epitope with the C-terminal of BLyS (TT-BLyS). This vaccine can induce high titers of neutralizing antibodies against BLyS in an animal model; the antibody has markedly protective effects on experimental autoimmune encephalomyelitis in rats, which is induced by inoculation of spinal cord homogenate. Our data suggest that the BLyS Autovaccine may be a useful candidate for the treatment of some autoimmune diseases associated with the production of BLyS.

  • Prepared and screened a modified TNF-α molecule as TNF-α Autovaccine to treat LPS induced endotoxic shock and TNF-α induced cachexia in mouse
    Cellular immunology, 2007
    Co-Authors: Yi Wan, Xiaochang Xue, Xin Qin, Cun Zhang, Weihua Wang, Xiaoyong Zhang, Yanjie You, Changli Jiang
    Abstract:

    Abstract Overexpression of TNF-α in the body is critically involved in many diseases. A strategy to construct TNF-α Autovaccine by introducing a T cell helper epitope to the protein has been developed and may be an alternative because it is cheaper and highly efficient. However, the induction of high level anti-TNF-α neutralizing autoantibodies by TNF-α Autovaccine is depend on a proper T cell help epitope. In order to evaluate the effect of different T helper cell epitopes on the immunogenicity of mouse TNF-α (mTNF-α), three T helper cell epitopes, TT (QYIKANSKFIGITEL), HEL (NTDGSTDYGILQINSR), and PADRE (AKFVAAWTLKA), were chosen for this study. The sequence (amino acids 126–140) of mTNF-α was replaced with those of the T cell help epitopes, respectively. The three fusion proteins (mTNF-TT, mTNF-HEL, mTNF-PADRE) were expressed in Escherichia coli and purified with a simple strategy. The abilities of the proteins elicited TNF-α autoantibodies in BALB/c mice were investigated. The results showed that mTNF-PADRE is the most effective among the three modified TNF-α molecules. In the absence of adjuvant, the therapeutic effect of TNF-PADRE on LPS induced endotoxic shock mice and mTNF-α induced cachexia mice was observed. This study suggests that mTNF-PADRE may be a better candidate of mTNF-α Autovaccine.

Xiaochang Xue - One of the best experts on this subject based on the ideXlab platform.

  • Therapeutic effects of PADRE-BAFF Autovaccine on rat adjuvant arthritis.
    BioMed research international, 2014
    Co-Authors: Guodong Feng, Xiaochang Xue, Meili Gao, Xianfeng Wang, Zhen Shu, Yuan Gao, Zenglu Wang, Qiang Hao
    Abstract:

    B cell activating factor (BAFF) is a cytokine of tumor necrosis factor family mainly produced by monocytes and dendritic cells. BAFF can regulate the proliferation, differentiation, and survival of B lymphocytes by binding with BAFF-R on B cell membrane. Accumulating evidences showed that BAFF played crucial roles and was overexpressed in various autoimmune diseases such as systemic lupus erythematous (SLE) and rheumatoid arthritis (RA). This suggests that BAFF may be a therapeutic target for these diseases. In the present study, we developed a BAFF therapeutic vaccine by coupling a T helper cell epitope AKFVAAWTLKAA (PADRE) to the N terminus of BAFF extracellular domains (PADRE-BAFF) and expressed this fusion protein in Escherichia coli. The purified vaccine can induce high titer of neutralizing BAFF antibodies and ameliorate the syndrome of complete Freund’s adjuvant (CFA) induced rheumatoid arthritis in rats. Our data indicated that the BAFF Autovaccine may be a useful candidate for the treatment of some autoimmune diseases associated with high level of BAFF.

  • The preventive effect of adjuvant-free administration of TNF-PADRE Autovaccine on collagen-II-induced rheumatoid arthritis in mice.
    Cellular immunology, 2009
    Co-Authors: Yi Wan, Shi-fang Yuan, Xiaochang Xue, Xin Qin, Cun Zhang, Weihua Wang, Changli Jiang, Yan Liu
    Abstract:

    Adjuvants are necessary to elicit high titers of antibodies in vaccine-immunization procedures. We previously developed a mouse tumor necrosis factor-α (TNF-α) Autovaccine (mTNF-PADRE) capable of inducing anti-TNF-α antibodies. In this study, we investigated the therapeutic effect of adjuvant-free administration of the Autovaccine on collagen-type-II-induced rheumatoid arthritis (CIA) in mice. Our results showed that the vaccine could ameliorate the symptoms of CIA in mice. In addition, this study suggests that it is possible to control the antibody levels in mice immunized with mTNF-PADRE without adjuvant.

  • Amelioration of experimental autoimmune encephalomyelitis by BLyS Autovaccine
    Vaccine, 2008
    Co-Authors: Xiaochang Xue, Xin Qin, Cun Zhang, Weihua Wang, Changli Jiang, Yanjie You, Guodong Feng, Yan Liu
    Abstract:

    The B-lymphocyte stimulator (BLyS) is implicated in various pathophysiological processes. The overexpression of BLyS has been observed in some human diseases, including systemic lupus erythematosus, rheumatoid arthritis, Sjogren's syndrome, and multiple sclerosis. This feature suggests that BLyS may be a therapeutic target for some human autoimmune diseases. We developed a therapeutic vaccine by coupling a tetanus toxoid T-helper cell epitope with the C-terminal of BLyS (TT-BLyS). This vaccine can induce high titers of neutralizing antibodies against BLyS in an animal model; the antibody has markedly protective effects on experimental autoimmune encephalomyelitis in rats, which is induced by inoculation of spinal cord homogenate. Our data suggest that the BLyS Autovaccine may be a useful candidate for the treatment of some autoimmune diseases associated with the production of BLyS.

  • Prepared and screened a modified TNF-α molecule as TNF-α Autovaccine to treat LPS induced endotoxic shock and TNF-α induced cachexia in mouse
    Cellular immunology, 2007
    Co-Authors: Yi Wan, Xiaochang Xue, Xin Qin, Cun Zhang, Weihua Wang, Xiaoyong Zhang, Yanjie You, Changli Jiang
    Abstract:

    Abstract Overexpression of TNF-α in the body is critically involved in many diseases. A strategy to construct TNF-α Autovaccine by introducing a T cell helper epitope to the protein has been developed and may be an alternative because it is cheaper and highly efficient. However, the induction of high level anti-TNF-α neutralizing autoantibodies by TNF-α Autovaccine is depend on a proper T cell help epitope. In order to evaluate the effect of different T helper cell epitopes on the immunogenicity of mouse TNF-α (mTNF-α), three T helper cell epitopes, TT (QYIKANSKFIGITEL), HEL (NTDGSTDYGILQINSR), and PADRE (AKFVAAWTLKA), were chosen for this study. The sequence (amino acids 126–140) of mTNF-α was replaced with those of the T cell help epitopes, respectively. The three fusion proteins (mTNF-TT, mTNF-HEL, mTNF-PADRE) were expressed in Escherichia coli and purified with a simple strategy. The abilities of the proteins elicited TNF-α autoantibodies in BALB/c mice were investigated. The results showed that mTNF-PADRE is the most effective among the three modified TNF-α molecules. In the absence of adjuvant, the therapeutic effect of TNF-PADRE on LPS induced endotoxic shock mice and mTNF-α induced cachexia mice was observed. This study suggests that mTNF-PADRE may be a better candidate of mTNF-α Autovaccine.

Yan Liu - One of the best experts on this subject based on the ideXlab platform.

  • The preventive effect of adjuvant-free administration of TNF-PADRE Autovaccine on collagen-II-induced rheumatoid arthritis in mice.
    Cellular immunology, 2009
    Co-Authors: Yi Wan, Shi-fang Yuan, Xiaochang Xue, Xin Qin, Cun Zhang, Weihua Wang, Changli Jiang, Yan Liu
    Abstract:

    Adjuvants are necessary to elicit high titers of antibodies in vaccine-immunization procedures. We previously developed a mouse tumor necrosis factor-α (TNF-α) Autovaccine (mTNF-PADRE) capable of inducing anti-TNF-α antibodies. In this study, we investigated the therapeutic effect of adjuvant-free administration of the Autovaccine on collagen-type-II-induced rheumatoid arthritis (CIA) in mice. Our results showed that the vaccine could ameliorate the symptoms of CIA in mice. In addition, this study suggests that it is possible to control the antibody levels in mice immunized with mTNF-PADRE without adjuvant.

  • Amelioration of experimental autoimmune encephalomyelitis by BLyS Autovaccine
    Vaccine, 2008
    Co-Authors: Xiaochang Xue, Xin Qin, Cun Zhang, Weihua Wang, Changli Jiang, Yanjie You, Guodong Feng, Yan Liu
    Abstract:

    The B-lymphocyte stimulator (BLyS) is implicated in various pathophysiological processes. The overexpression of BLyS has been observed in some human diseases, including systemic lupus erythematosus, rheumatoid arthritis, Sjogren's syndrome, and multiple sclerosis. This feature suggests that BLyS may be a therapeutic target for some human autoimmune diseases. We developed a therapeutic vaccine by coupling a tetanus toxoid T-helper cell epitope with the C-terminal of BLyS (TT-BLyS). This vaccine can induce high titers of neutralizing antibodies against BLyS in an animal model; the antibody has markedly protective effects on experimental autoimmune encephalomyelitis in rats, which is induced by inoculation of spinal cord homogenate. Our data suggest that the BLyS Autovaccine may be a useful candidate for the treatment of some autoimmune diseases associated with the production of BLyS.

Yi Wan - One of the best experts on this subject based on the ideXlab platform.

  • The preventive effect of adjuvant-free administration of TNF-PADRE Autovaccine on collagen-II-induced rheumatoid arthritis in mice.
    Cellular immunology, 2009
    Co-Authors: Yi Wan, Shi-fang Yuan, Xiaochang Xue, Xin Qin, Cun Zhang, Weihua Wang, Changli Jiang, Yan Liu
    Abstract:

    Adjuvants are necessary to elicit high titers of antibodies in vaccine-immunization procedures. We previously developed a mouse tumor necrosis factor-α (TNF-α) Autovaccine (mTNF-PADRE) capable of inducing anti-TNF-α antibodies. In this study, we investigated the therapeutic effect of adjuvant-free administration of the Autovaccine on collagen-type-II-induced rheumatoid arthritis (CIA) in mice. Our results showed that the vaccine could ameliorate the symptoms of CIA in mice. In addition, this study suggests that it is possible to control the antibody levels in mice immunized with mTNF-PADRE without adjuvant.

  • Prepared and screened a modified TNF-α molecule as TNF-α Autovaccine to treat LPS induced endotoxic shock and TNF-α induced cachexia in mouse
    Cellular immunology, 2007
    Co-Authors: Yi Wan, Xiaochang Xue, Xin Qin, Cun Zhang, Weihua Wang, Xiaoyong Zhang, Yanjie You, Changli Jiang
    Abstract:

    Abstract Overexpression of TNF-α in the body is critically involved in many diseases. A strategy to construct TNF-α Autovaccine by introducing a T cell helper epitope to the protein has been developed and may be an alternative because it is cheaper and highly efficient. However, the induction of high level anti-TNF-α neutralizing autoantibodies by TNF-α Autovaccine is depend on a proper T cell help epitope. In order to evaluate the effect of different T helper cell epitopes on the immunogenicity of mouse TNF-α (mTNF-α), three T helper cell epitopes, TT (QYIKANSKFIGITEL), HEL (NTDGSTDYGILQINSR), and PADRE (AKFVAAWTLKA), were chosen for this study. The sequence (amino acids 126–140) of mTNF-α was replaced with those of the T cell help epitopes, respectively. The three fusion proteins (mTNF-TT, mTNF-HEL, mTNF-PADRE) were expressed in Escherichia coli and purified with a simple strategy. The abilities of the proteins elicited TNF-α autoantibodies in BALB/c mice were investigated. The results showed that mTNF-PADRE is the most effective among the three modified TNF-α molecules. In the absence of adjuvant, the therapeutic effect of TNF-PADRE on LPS induced endotoxic shock mice and mTNF-α induced cachexia mice was observed. This study suggests that mTNF-PADRE may be a better candidate of mTNF-α Autovaccine.